KR20060019579A - 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제 - Google Patents

병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제 Download PDF

Info

Publication number
KR20060019579A
KR20060019579A KR1020057023543A KR20057023543A KR20060019579A KR 20060019579 A KR20060019579 A KR 20060019579A KR 1020057023543 A KR1020057023543 A KR 1020057023543A KR 20057023543 A KR20057023543 A KR 20057023543A KR 20060019579 A KR20060019579 A KR 20060019579A
Authority
KR
South Korea
Prior art keywords
angiogenesis
edema
retinal
steroidal anti
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057023543A
Other languages
English (en)
Korean (ko)
Inventor
데이빗 피. 빈가맨
Original Assignee
알콘, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘, 인코퍼레이티드 filed Critical 알콘, 인코퍼레이티드
Publication of KR20060019579A publication Critical patent/KR20060019579A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020057023543A 2003-06-13 2004-06-14 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제 Withdrawn KR20060019579A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47825203P 2003-06-13 2003-06-13
US47822703P 2003-06-13 2003-06-13
US60/478,227 2003-06-13
US60/478,252 2003-06-13

Publications (1)

Publication Number Publication Date
KR20060019579A true KR20060019579A (ko) 2006-03-03

Family

ID=33544369

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057023543A Withdrawn KR20060019579A (ko) 2003-06-13 2004-06-14 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제

Country Status (10)

Country Link
US (2) US20040259765A1 (enExample)
EP (1) EP1633339A4 (enExample)
JP (1) JP2007500250A (enExample)
KR (1) KR20060019579A (enExample)
AU (1) AU2004249167A1 (enExample)
BR (1) BRPI0411427A (enExample)
CA (1) CA2527121A1 (enExample)
MX (1) MXPA05012696A (enExample)
RU (1) RU2006101150A (enExample)
WO (1) WO2004112772A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528718A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
JP5668476B2 (ja) * 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
MX338355B (es) * 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
CA1331559C (en) * 1986-04-21 1994-08-23 Jon Joseph Kabara Antimicrobial preservative compositions and methods
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AU1970197A (en) * 1996-05-09 1997-11-26 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6413245B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
ES2231257T3 (es) * 1999-10-21 2005-05-16 Alcon Inc. Dispositivo para la administracion de farmacos.
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AU2002247284A1 (en) * 2001-04-02 2002-10-15 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac

Also Published As

Publication number Publication date
JP2007500250A (ja) 2007-01-11
EP1633339A4 (en) 2009-06-03
AU2004249167A1 (en) 2004-12-29
RU2006101150A (ru) 2006-06-10
US20040259765A1 (en) 2004-12-23
US20070043006A1 (en) 2007-02-22
EP1633339A1 (en) 2006-03-15
BRPI0411427A (pt) 2006-07-25
MXPA05012696A (es) 2006-02-22
CA2527121A1 (en) 2004-12-29
WO2004112772A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
JP2009511604A (ja) 緑内障の原発性形態および続発性形態を処置するための方法
US20070134244A1 (en) Combination treatment for pathologic ocular angiogenesis
EP3359257B1 (en) Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
KR20120040683A (ko) 디플루프레드네이트를 포함하는 황반부종 치료용 점안액
US20060154910A1 (en) Use of steroids to treat ocular disorders
CN100431544C (zh) 用于治疗病理性眼血管生成的糖皮质激素制剂
KR20060019579A (ko) 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제
JP2007500250A5 (enExample)
CN100353947C (zh) 以甾体为有效成分的视网膜和脉络膜疾病治疗剂
Pérez-Sarriegui et al. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant
ZA200509532B (en) Formulations or non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
Arevalo et al. Pseudophakic Cystoid Macular Edema
US20090181933A1 (en) Use of steroids to treat persons suffering from ocular disorders
Ahuja et al. Post-operative assesment of single subconjunctival triamcinolone acetate injection vs topical corticosteroid in cataract surgery: A prospective control study
CN1802151A (zh) 用于治疗病理性眼内血管生成的非甾体类抗炎药制剂
Amol The Posurdex biodegradable intravitreal extended-release implant
KR20080078042A (ko) 여과포 수술중 보조제로서 아네코르타브 아세테이트의 용도
Scheinblum et al. Drug therapy before, during, and after cataract surgery
Moustafa et al. Intraocular Pressure Monitoring after Intravitreal Injection of Triamcinolone
Sánchez et al. Treatment of Inflammation Secondary to Vitreoretinal Surgery

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid